Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal ...

The U.S. Department of Education has announced an allocation of $179 million in grants aimed at fostering academic ...

Moreover, CLSD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises ...

Clearside Biomedical Inc (CLSD) stock saw a modest uptick, ending the day at $1.06 which represents a slight increase of $0.09 or 9.28% from the prior close of $0.97. The stock opened at $1 and ...

What happened: The Cornwall-Lebanon School District has about 200 students who want to attend the Lebanon County Career and ...

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical (CLSD – Research ...

Louisiana is poised to receive $70 million from the U.S. Department of Education to improve reading instruction at high-need ...

Short interest in Clearside Biomedical Inc (NASDAQ:CLSD) increased during the last reporting period, rising from 180.15K to 335.17K. This put 0.48% of the company's publicly available shares short.

View Clearside Biomedical, Inc. (CLSD) current and estimated P/E ratio data provided by Seeking Alpha.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...